Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study

Supportive Care in Cancer

Volumn 21, Issue 1, 2013, Pages 129-137

  Garcia, José M ^a,b   Friend, John ^c   Allen, Suzan ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Helsinn Therapeutics (US) Inc   (United States)

Author keywords

Anorexia; Biomarkers; Body weight; Growth hormone

Indexed keywords

ANAMORELIN; GROWTH HORMONE; PLACEBO; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; CACHEXIA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOOD INTAKE; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LYMPHADENOPATHY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; APPETITE; APPETITE STIMULANTS; BIOLOGICAL MARKERS; CACHEXIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GHRELIN; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; UNITED STATES; WEIGHT GAIN;

EID: 84874083358     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1500-1     Document Type: Article

References (43)

1. Lasheen W, Walsh D (2010) The cancer anorexia-cachexia syndrome: myth or reality? Support Care Cancer 18:265-272
2. Tisdale MJ (2009) Mechanisms of cancer cachexia. Physiol Rev 89:381-410
3. Adamopoulos S, Parissis JT, Georgiadis M et al (2002) Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 144:359-364
4. Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10:50. doi: 10.1186/1471-2407-10-50
5. Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497
6. Davidoff AJ, Tang M, Seal B, Edelman MJ (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28:2191-2197. doi: 10.1200/JCO.2009.25.4052
7. Mantovani G, Madeddu C (2010) Cancer cachexia: medical management. Support Care Cancer 18:1-9. doi: 10.1007/s00520-009-0722-3
8. Neary NM, Small CJ, Wren AM et al (2004) Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2832-2836. doi: 10.1210/jc.2003-031768
9. Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care: correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 103:2189-2198. doi: 10.1002/cncr.21013
10. Morley JE, Thomas DR, Wilson M-MG (2006) Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 83:735-743
11. Crown AL, Cottle K, Lightman SL et al (2002) What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf) 56:723-733. doi: 10.1046/j.1365-2265.2002.01540.x
12. Strasser F, Lutz TA, Maeder MT et al (2008) Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 98:300-308. doi: 10.1038/sj.bjc.6604148
13. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
14. Wren AM, Seal LJ, Cohen MA et al (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86:5992. doi: 10.1210/jc.86.12.5992
15. Garcia JM, Polvino WJ (2007) Effect on body and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12:594-600
16. Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19:267-273. doi: 10.1016/j.ghir.2008.12. 003
17. Nass R, Pezzoli SS, Oliveri MC et al (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149:601-611
18. Akamizu T, Takaya K, Irako T et al (2004) Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocr 150:447-455. doi: 10.1530/eje.0.1500447
19. World Medical Association: The World Medical Association: policy: World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Amendments through 55th WMA General Assembly, Tokyo; 2004. Available at: 40news/20archives/2004/2004-24/index.html. Accessed February 8, 2011
20. United States Food and Drug Administration, Department of Health and Human Services: FDA Good Clinical Practice Program. Available at http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ ucm155713.htm. Accessed February 8, 2011
21. European Union Directive 91/507/EEC: Commission Directive 91/507/EEC of 19 July 1991: modifying the Annex to Council Directive 75/318/EEC on the approximation of the laws of member states relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products. Available at http://eur-lex.europa.eu/smartapi/ cgi/sga-doc?smartapi!celexplus!prod!DocNumber&lg=en&type-doc= Directive&an-doc=1991&nu-doc=507. Accessed February 8, 2011
22. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
23. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191-196
24. Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88:2164-2171
25. Palmer JL, Fisch MJ (2005) Association between symptom distress and survival in outpatients seen in a palliative care cancer center. J Pain Symptom Manag 29:565-571. doi: 10.1016/j.jpainsymman.2004.11.007
26. Robinson DW Jr, Eisenberg DF, Cella D et al (2008) The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 6:283-290
27. Cella DF, VonRoenn J, Lloyd S, Browder HP (1995) The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia. Qual Life Res 4:221-231
28. McMillan DC (2009) Systemic inflammation, nutritional status, and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223-226
29. Garcia JM, Garcia-Touza M, Hijazi RA et al (2005) Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 90:2920-2926. doi: 10.1210/jc.2004-1788
30. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518
31. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124:2416-2429
32. Han J, Jogie-Brahim S, Harada A, Oh Y (2011) Insulin-like growth factor-binding protein-3 suppresses tumor growth via activation of caspase-dependent apoptosis and cross-talk with NF-κB signaling. Cancer Lett 307:200-210. doi: 10.1016/j.canlet.2011.04.004
33. Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY (2011) Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood 118:2622-2631. doi: 10.1182/blood-2010-08-299784
34. Wolf RF, Ng B, Weksler B, Burt M, Brennan MF (1994) Effect of growth hormone on tumor and host in an animal model. Ann Surg Oncol 1:314-320
35. Hanada T, Toshinai K, Kajimura N et al (2003) Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 301:275-279
36. Bartlett DL, Charland S, Torosian MH (1994) Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer 73:1499-1504
37. Bartlett DL, Stein TP, Torosian MH (1995) Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery 117:260-267
38. Rohrmann S, Linseisen J, Becker S et al (2011) Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 20:2174-2182
39. Lundholm K, Gunnebo L, Korner U et al (2010) Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 116:2044-2052. doi: 10.1002/cncr.24917
40. Ghigo E, Arvat E, Broglio F et al (1999) Endocrine and non-endocrine activities of growth hormone secretagogues in humans. Horm Res 51(suppl 3):9-15
41. Fearon KC (2011) Cancer cachexia and fat-muscle physiology. N Engl J Med 365:565-567
42. American Thoracic Society/American College of Chest Physicians (2003) Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167:211-277
43. Jakobsen LH, Rask IK, Kondrup J (2010) Validation of handgrip strength and endurance as a measure of physical function and quality of life in healthy subjects and patients. Nutrition 26:542-550